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Abstract
Background: Hypertension (HTN) is a ubiquitous risk factor for numerous non-communicable diseases, including
cardiovascular disease and stroke. There are currently no wholly effective pharmacological therapies for subjects
with HTN. However, salt substitutes have emerged as a potential therapy for the treatment of HTN. The aim of the
present study was to assess the effect of salt substitutes on reducing systolic blood pressure (SBP) and diastolic BP
(DBP), following a meta-analysis of randomized controlled trials.
Methods: Studies were found via systematic searches of the Pubmed/Medline, Scopus, Ovid, Google Scholar and
Cochrane library. Ten studies, comprised of 11 trials and 1119 participants, were included in the meta-analysis.
Results: Pooled weighted mean differences showed significant reductions of SBP (WMD − 8.87 mmHg; 95% CI −
11.19, − 6.55, p < 0.001) and DBP (WMD − 4.04 mmHg; 95% CI − 5.70, − 2.39) with no statistically significant
heterogeneity between the 11 included comparisons of SBPs and DBPs. The stratified analysis of trials based on the
mean age of participants showed a significant reduction in the mean difference of SBP in both adults (< 65 years
old) and elderly (≥65 years old). However, the DBP-lowering effect of salt substitutes was only observed in adult
patients (WMD − 4.22 mmHg; 95% CI − 7.85, − 0.58), but not in the elderly subjects.
Conclusions: These findings suggest that salt-substitution strategies could be used for lowering SBP and DBP in
patients with stage 2 HTN; providing a nutritional platform for the treatment, amelioration, and prevention of HTN.
Keywords: Hypertension, Salt substitutes, Systolic blood pressure, Diastolic blood pressure, Meta-analysis
Background
Hypertension (HTN) is characterized by a diastolic
blood pressure (DBP) (≥90 mmHg) and a systolic blood
pressure (SBP) (≥140 mmHg) [1]. Recently, HTN has
been asserted to be the leading cause of global disability-
adjusted life years [2]; whilst more than 25% of adults
are diagnosed with HTN, globally, and it is predicted
that by 2025, 29% (1.56 billion) of the adult population
will be affected [3]. New insights into the pathogenesis
of HTN has suggested that a variety of risk factors con-
tribute to the disease and may be modulated by various
cellular and molecular mechanisms [4, 5]. Such muta-
tions have been putatively linked to HTN pathogenesis;
specifically, mutations of Cyp11b1 and 11β-hydroxylase
are associated with the progression of HTN, albeit in
animal models [4, 5].
Cardiotonic steroids (CTSs) are a branch of hormones
mechanistically related to natriuresis, the process of so-
dium excretion in the urine, and are believed to play an
essential role in the pathogenesis of HTN, and exert im-
pact via interaction with Na/K-ATPase, which regulates
renal salt handling and help maintain the salt-sensitivity of
blood pressure (BP) [6]. In addition to genetic predispos-
ition, diet represents a major factor in the occurrence and
progression of HTN. Indeed, among dietary supplements,
salt substitutes have been purported to hold a potentially
pivotal role in the manifestation and progression of HTN.
Additionally, it has been reported that aging is directly re-
lated to the severity of HTN; where it has been shown that
after the age of 60 years, the prevalence of stage 2 HTN
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equates to 48.8% in individuals aged 60–79 years, and 63%
those aged over 80 years, respectively [7]. Therefore, achiev-
ing a suitable control in elderly women is difficult [8]. Given
that 62% of cardiovascular disorders, and 49% of ischemic
heart disease, are associated with elevated BP, efficacious
dietary interventions are highly sought-after. The Food and
Agriculture Organization of the United Nations and World
Health Organization have advocated that the consumption
of less than 5 g of salt per day as a preventative measure
against HTN; whilst further research has asserted that a de-
crease in salt consumption would likely result the reduction
of global incidence of HTN, cardiovascular disease, and
stroke related deaths [9]. A meta-analysis of randomized
controlled trials, conducted by Peng et al., documented the
impact of salt substitution on BP [10], where six cohorts
from 5 articles (1974 subjects) were included; demonstrat-
ing that salt substitutes elicit significant ameliorative effects
on SBP and DBP. Moreover, significant heterogeneity was
observed for both SBP and DBP [10]. Notwithstanding the
positive contribution made in [10], numerous limitations
were present, including high heterogeneity, low sample size
and limited included studies. Given such limitations exist,
in addition to the potential for salt substitutes to aid in the
amelioration or prevention of stage 2 HTN among adults
and the elderly, the aims of the present study were; firstly,
to provide an updated systematic review and meta-analysis
of the hypotensive effects of salt substitutes, as manifest
in randomized controlled trials (RCTs) in subjects with
stage 2 HTN, and secondly, perform additional analyses
investigating the effect of potential modulators which
may interfere with the BP-lowering effect of salt substi-
tutes, including participants age, duration of adminis-
tration, and quality of studies.
Methods
Search strategy and selection of studies
The Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines were adopted
to perform this systematic review and meta-analysis [11].
Initially, a systematic search of the electronic databases;
Pubmed/Medline™, Scopus™, Ovid™, Google Scholar™
and Cochrane library™, up to December 2018 for studies
relating to the main intervention and outcome, was con-
ducted. In addition, we reviewed the reference lists of
relevant original and previous review articles in order to
identify further eligible studies. The following search
terms were employed: “salt substitution” OR “salt substi-
tute” OR salt OR sodium OR potassium, in combination
with; “Blood pressure” OR “Hemodynamic parameters”
OR “BP” OR “SBP” OR “Systolic blood pressure” OR
“DBP” OR “Diastolic blood pressure”. No restrictions in
published languages were imposed. In the case of insuffi-
cient data, we contacted the authors of the studies to
request the necessary information.
Clinical trials investigating the effects of salt substitutes
on blood pressure were selected for the meta-analysis if
they satisfied the following inclusion criteria: being a RCT
of either parallel or cross-over design, participants were
diagnosed with stage 2 HTN (SBP ≥ 140mmHg or DBP ≥
90mmHg) according to the recent American College of
Cardiology/American Heart Association (ACC/AHA) up-
dated guidelines [12], investigating the effects of salt sub-
stitutes, in any form, on blood pressure, reporting either
blood pressure levels or mean change of both intervention
and control groups before and after the trials. Exclusion
criteria were: 1) low quality of study (less than two on the
Jadad scale); 2) lack of a control group for salt substitute,
2) inadequate reporting data on SBP or DBP in interven-
tion and control groups or data for calculating the mean
change of outcomes.
Data extraction and quality assessment
Two authors independently screened the data and ex-
cluded those not of relevance, and possible discrepancies
were resolved through discussion with a third author.
We extracted the following characteristics of each eli-
gible study: first author’s name, study design, study loca-
tion, sample size of intervention and control groups, age,
follow-up duration, dosage and ingredients of salt and
salt substitute, clinical condition and stage of hyperten-
sion of participants, baseline SBP and DBP levels, and
quality of trials.
We assessed the quality of the included study by using
the Jadad scale, that ranges from 0 to 5, with the follow-
ing descriptions: (1) randomization (one point for stating
random allocation and additional point for appropriate
description of the method), (2) blinding (one point for
stating the blindness of the trial and one additional point
if the method of blinding was appropriate), and (3)
reporting of participant withdrawals (one point if the
outcome of all participants is known). The studies with
the total score of ≥3 considered as high-quality trials.
Statistical analysis
Results were expressed as the weighted mean difference
(WMD) in systolic and diastolic blood pressure with
95% confidence intervals (CI). We calculated the net
changes in outcomes in both intervention and control
groups, as the differences between mean values before
and after treatments in parallel trials. In crossover trials,
we measured the net changes as the differences in the
post treatment values of each group. We calculated SD
values in the studies with no reported SD, by using the
standardized method of Follman [13]. The heterogeneity
between the studies was assessed by using the I2 test and
Cochrane’s Q test at by which P < 0.05 or I2 > 50% was
identified as heterogeneous. A random effects model was
utilized if significant heterogeneity was evident. Otherwise,
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the fixed-effects model was used. We used stratified ana-
lysis to detect any possible influences of several modulators,
including; clinical condition and stage of hypertension of
participants, baseline systolic and diastolic blood pressure
and duration of intervention. We also conducted a sensitiv-
ity analysis by omitting a single study and re-calculating the
effect size to explore its influence on the overall effect size.
We explored the potential publication bias by using Funnel
plot, Begg’s rank correlation test and Egger’s weighted re-
gression test.
All analyses were conducted using Review Manager
Software (Review Manager 5.3; Cochrane Collaboration,
Oxford, England) and Comprehensive Meta-Analysis (ver-
sion 3.2; Biostat). A P value of less than 0.05 was considered
as statistically significant in the present meta-analysis.
Results
Study selection
An overview of the selection process is shown in Fig. 1.
The initial literature search identified 818 studies. After re-
moval of duplicates, non-relevant papers, unavailable full-
text papers, and non-original studies, including reviews, let-
ters, editorials and case reports, 20 studies were fully
reviewed, and another 10 studies were excluded because
they did not meet the inclusion criteria for the meta-
analysis. The reasons for the exclusion were: concomitant
interventions, intervention duration of less than 8 days, in-
sufficient data regarding baseline and final values of SBP
and DBP, lack of control group and inappropriate design
including low quality of the study. Yang et al. [14] investi-
gated the effect of salt substitutes on different subsets
separated by various characteristics of participants and ac-
cording to the Cochrane Handbook for Systematic Reviews
of Interventions [15], each arm was considered as an inde-
pendent trial in the present meta-analysis. Finally, ten stud-
ies, with 11 trials and 1119 participants were included in
the present meta-analysis [16–24].
Study characteristics
Characteristics of included trials are shown in Table 1.
The included trials enrolled 546 male and female partici-
pants in intervention and 573 participants in control
groups (total participants of 1119), with a mean age ran-
ging between 39.5 and 67.8 years. These 11 included tri-
als were published between 1986 to 2018, of which five
were conducted in China [14, 21, 22, 24], two in Brazil
[17, 25], and one in Finland [20], France [26], Italy [27]
and the UK [28], respectively. The intervention duration
ranged between 8 days and 24months. All trials used
common salt (NaCl) as the salt type for control groups
[14, 20–22, 24–28], except for Barros et al. who used
390 mg of sodium and 25 mcg of iodine per gram of salt
[17]. The included trials used a combination of NaCl,
KCl and MgSo2/MgSo4 as salt substitutes. Other
micronutrients, such as calcium, folic acid, and trace
minerals were used as co-ingredients of salt substitutes.
Sample sizes ranged from 5 to 238, with 546 total partic-
ipants in the intervention groups and 573 in the control
groups, respectively. The mean SBP of intervention
groups at baseline varied between 136.2 and 174.1
mmHg, and the mean DBP between 80.6 and 102.2
mmHg.
Study quality
Risk of bias assessments were performed for all 11 trials in-
cluded in the meta-analysis and are summarized in Fig. 2.
The Jadad score of these trials was relatively high, and most
included trials had a score of more than 3. As it has been
shown in previous studies, in which the scores of more than
three are considered as high quality, six trials are catego-
rized as high-quality studies [17, 21, 22, 24–26] and the
remaining trials were divided into low quality studies
[14, 20] and unclear quality studies [27, 28] (Table 2).
Effect of salt substitutes on blood pressure
The results of the meta-analysis, including the 11 trials, are
presented in Fig. 2. Pooled weighted mean differences
showed the significant reductions of SBP (WMD − 8.87
mmHg; 95% CI − 11.19, − 6.55, p < 0.001) and DBP (WMD
− 4.04mmHg; 95% CI − 5.70, − 2.39) values. No statistically
significant heterogeneity was observed between the 11 in-
cluded comparisons of SBPs and DBPs (I2 = 0%). However,
we performed stratified analysis to further explore any po-
tential effect of modulators on overall results.
Stratified analysis
Subgroup analyses were carried out according to different
modulators, including duration of intervention, mean age of
participants in intervention groups, and quality of studies
(Table 3). The duration of intervention was divided into < 3
months (shorter-term) and ≥ 3months (longer-term). An-
other subgroup was based on the mean age of participants
in intervention groups, in which trials were separated as
adult (< 65 years old) and elderly (≥65 years old). Final sub-
group analysis related to the quality of studies, in which two
distinct categories were presented, as high-quality studies
and low-quality studies. Significant reductions in SBP (7.93
mmHg), and DBP (5.02mmHg) in shorter-term, and SBP
(9.78mmHg) and DBP (3.71mmHg) in longer-term sub-
groups were observed after salt substitute intervention. The
stratified analysis of trials based on the mean age of partici-
pants showed a significant reduction in the mean difference
of SBP in both adult (< 65 years old) (WMD − 10.38mmHg;
95% CI − 16.16, − 4.60) and elderly participants (≥65 years
old) (WMD − 9.98mmHg; (95% CI − 12.33, − 5.95)). How-
ever, the DBP-lowering effect of salt substitutes was only ob-
served in adult (< 65 years old) patients (WMD − 4.22
mmHg; 95% CI − 7.85, − 0.58), but not in the elderly (≥65
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years old) (WMD − 3.09 mmHg; 95% CI − 6.45, 0.27).
After stratified analysis according to the study quality,
both SBP and DBP were reduced by 9.14mmHg (95% CI
− 12.33, − 5.95) and 4.98mmHg (95% CI − 7.05, − 2.91),
respectively. However, the BP-lowering effect of salt
substitute in low quality studies was only related to SBP
(WMD: − 9.49mmHg; (95% CI − 14.15, − 4.84)), but not
DBP (WMD: − 2.13mmHg; (95% CI − 5.02, 0.77)).
Fig. 1 Flow diagram of literature search of the present meta-analysis
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Sensitivity analysis
Sensitivity analysis was performed by removing each trial
in turn and recalculating the pooled WMD. The system-
atic removal of each trial did not change the pooled effects
of salt substitute on SBP and DBP values, which ranged
from − 8.32 (95% CI = -10.85, − 5.79) to − 9.30 (95% CI = -
11.81, − 6.79) in SBP, and − 3.65 (95% CI = -5.48, − 1.82)
to − 4.75 (95% CI = -6.56, − 2.93) in DBP values (Fig. 3).
Publication Bias
Visual inspection of the funnel plots of standard error by
effect size (WMD) of both SBP and DBP were symmet-
rical, indicating no potential publication biases in the
present meta-analysis. Additionally, results from Egger’s
linear regression [SBP (intercept: 0.13; standard error:
0.55; 95% CI: − 1.11, 1.39; t = 0.25, df = 9; two-tailed
p = 0.80); DBP (intercept: − 0.53; standard error: 0.84; 95%
Fig. 2 Forest plot of comparison of blood pressure between salt substitutive and control groups. a systolic blood pressure and (b) diastolic blood
pressure. Random effects model was used to estimate the weighted mean differences of indicators. CI, confidence interval; I-squared inconsistency
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CI: − 2.49, 1.42; t = 0.63, df = 8; two-tailed p = 0.54)] and
Begg’s rank correlation test (SBP: Kendall’s Tau with con-
tinuity correction: 0.07; z = 0.31; two-tailed p = 0.75; DBP:
Kendall’s Tau with continuity correction:0.00; z = 0.00;
two-tailed p = 1.00) also suggested no evidence of poten-
tial publication bias (Fig. 4).
Discussion
In the present systematic review and meta-analysis, we
found that supplementation with salt substitutes is asso-
ciated with significant decreases in both SBP and DBP.
Moreover, no significant heterogeneity was noted be-
tween the 11 included comparisons of SBP and DBP.
Table 2 Quality of the nine included studies by Jadad scale
Study; Year Blinding Randomization Withdrawals and dropouts descriptions Total Score
Allaert, 2013 1 1 1 3
Arzilli, 1986 Not clear Not clear Not clear Not clear
Barros, 2015 2 2 0 4
Gilleran, 1996 Not clear Not clear Not clear Not clear
Pereira, 2005 2 1 1 4
Sarkkinen, 2011 1 1 0 2
Yang(a), 2018 1 1 0 2
Yang(b), 2018 1 1 0 2
Zhao, 2014 2 2 1 5
Zhou, 2009 2 2 1 5
Zhou, 2013 2 2 1 5
Table 3 Subgroup analysis
Subgroup* WMD (95% CI) Test for overall effect Test for heterogeneity I2(%)
Duration of study (weeks)
< 3 months
SBP −7.93 [−11.23, −4.62] P < 0.001 P = 0.84 0
DBP −5.02 [−8.32, −1.72] P = 0.003 P = 0.97 0
≥3 months
SBP −9.78 [−13.03, −6.53] P < 0.001 P = 0.93 0
DBP −3.71 [− 5.63, − 1.79] P < 0.001 P = 0.53 0
Mean age of subjects
< 65 years old
SBP −10.38 [− 16.16, −4.60] P < 0.001 P = 0.83 0
DBP −4.22 [−7.85, −0.58] P = 0.02 P = 0.91 0
≥65 years old
SBP −9.98 [−14.06, −5.90] P < 0.001 P = 0.55 0
DBP −3.09 [−6.45, 0.27] P = 0.07 P = 0.18 42
Quality of studies
High quality
SBP −9.14 [−12.33, −5.95] P < 0.001 P = 0.86 0
DBP −4.98 [−7.05, −2.91] P < 0.001 P = 0.98 0
Low quality
SBP −9.49 [−14.15, −4.84] P < 0.001 P = 0.60 0
DBP −2.13 [−5.02, 0.77] P = 0.15 P = 0.47 0
*: Abbreviations: SBP Systolic blood pressure, DBP Diastolic blood pressure, WMD Weighted mean difference, CI Confidence interval, I2, percentage score
for heterogeneity
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Our results confirmed that both short and long-term
use yielded significant decreases in SBP and DBP. In
addition, stratified analysis showed a significant decrease
in the mean difference of SBP in both adult (< 65 years
old) and elderly (≥65 years old). However, the DBP-
lowering impacts of salt substitutes was only found in
adult patients, not in the elderly subjects.
HTN is an important risk factor for a wide range of
diseases, including cardiovascular diseases, stroke, and
various types of cancer. Despite concerted efforts, global
access to effective pharmacological treatments for HTN
remains challenging [29]. Salt substitutes have emerged
as an adjunct or mono-therapy in the treatment of HTN
and related diseases. Empirical evidence suggests that
salt substitutes exert their pharmacological effects via
targeting and affecting sequences of cellular and molecu-
lar processes. Results from empirical investigations sug-
gest that salt intake plays a role in the development of
Fig. 3 Sensitivity analysis for the effect of salt substitutes on (a) systolic blood pressure, b diastolic blood pressure
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HTN [30, 31]; whilst various RCTs have affirmed that
simply decreasing salt intake could elicit hypotensive ef-
fects in both hypertensive and normotensive subjects
[32, 33]. There are multiple mechanisms implicating the
potential benefits of salt restriction in the diet; high salt
consumption results in an increase in blood volume and
peripheral vascular resistance, thus, limiting salt intake
could facilitate a reduction in BP [34]. Additionally, salt
restriction could lead to decreased production and infil-
tration of inflammatory markers, consequently lowering
blood pressure [35]. Moreover, salt restriction has been
suggested as an inhibiting factor in the production of
ROS (reactive oxygen species), thus improving periph-
eral vascular resistance and subsequently reducing BP
[36]. International guidelines now suggest a population-
based salt restriction for the treatment and prevention of
HTN [37, 38], whilst at the seminal United Nations
Non-Communicable Disease Summit in 2011, the World
Health Organization supported a reduction in dietary
salt intake [39, 40].
The UK salt-reduction program is one of most influ-
ential programs worldwide, and has yielded significant
reductions in the salt content of several processed foods
through a food industry–level intervention [41]. Con-
trastingly, in developing countries, the main source of
dietary sodium is from home cooking [42]. Hence, it is
conceivable that salt-reduction approaches typically used
in developed countries could be ineffective and inappro-
priate in the developing world, and other approaches
must be assessed [41]. In the early 1990’s, a potassium-
Fig. 4 Funnel plot detailing publication bias of included studies according to (a) systolic blood pressure and (b) diastolic blood pressure. MD =
Mean Difference, SE = standard error
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and magnesium-enriched salt alternative was introduced
that effectively led to the reduced presence of sodium in
foods [43]. Subsequently, several epidemiologic reports
and clinical trials have investigated the hypotensive ef-
fects of salt substitutes [20, 22, 44].
Zhou et al., investigated the long-term impact of salt
substitution (comprised of 65% sodium chloride, 10%
magnesium sulfate, 25% potassium chloride) vs. normal
salt (100% sodium chloride) on BP among 200 families
in rural China [22]. Zhou et al., reported that SBP and
DBP were significantly reduced in normotensive sub-
jects, and SBP was reduced in hypertensive subjects.
These findings suggest that salt substitution may be in-
troduced as an efficacious adjuvant therapy for subjects
with HTN, and may be used in the prevention of HTN
in normotensive individuals [22]. In another report,
Zhou and colleagues assessed the therapeutic effects of
salt substitutes on subjects with HTN in a rural popula-
tion of North China [23]. Participants were dichoto-
mized into either a normal salt (100% sodium chloride)
or low salt substitute (65% NaCl, 10% MgSO4, and 25%
KCl), and the authors reported that the low sodium sub-
stitute led to a significant decrease in SBP and DBP, in
comparison to regular salt. Moreover, participants aged
40–70 years had a greater response to the salt substitute
than those aged < 40 or > 70 years, respectively; whilst
the low salt substitute was associated with heterogenous
benefits in both females and males.
Previous meta-analyses have investigated the effects of
salt substitutes on blood pressure [10, 45]. Indeed, Peng
et al., [10] documented that salt substitutes can elicit sig-
nificant reductions in SBP (− 4.9 mmHg) and DBP (− 1.5
mmHg). In the present systematic review and meta-
analysis, we provide greater clarity into the efficacious-
ness of salt substitutes for reducing blood pressure,
where we were able to include a greater number of rele-
vant studies (11 trials vs 6 trials), incorporated a larger
sample size, had low heterogeneity, and we also used
pre-specified subgroups to assess the impact of modera-
tors. The overarching result remains the same as previ-
ous work, however, we reported greater reductions in
both SBP (WMD − 8.87 mmHg; 95% CI − 11.19, − 6.55,
p < 0.001) and DBP (WMD − 4.04 mmHg; 95% CI −
5.70, − 2.39), which is likely attributable to the increased
number of studies included for meta-analysis.
Interestingly, a significant reduction in the mean dif-
ference of SBP in both adult (< 65 years old) and elderly
populations (≥65 years old) was detected, whereas the
DBP-lowering effect of salt substitutes was observed in
adult (< 65 years old) patients, but not in the elderly
(≥65 years old). Whilst both SBP and DBP are consid-
ered independent predictors of CVD in younger people,
SBP could be considered as a suitable predictor for eld-
erly subjects [46, 47]. Moreover, it is suggested that anti-
hypertensive agents be more acutely considered in eld-
erly persons, as although DBP was reduced to < 90
mmHg in 90% of subjects, SBP was lowered to < 140
mmHg in just 60% of elderly subjects [46, 47].
Salt substitutes have been principally shown to reduce
urinary sodium excretion and increase potassium excre-
tion in varying populations [24, 28]; we can therefore
assert that the reduction in BP that we observed in this
meta-analysis is likely attributable to the salt substitutes.
Of note, whilst perception or palatability of saltiness was
not investigated in this meta-analysis, it has been dem-
onstrated in previous work [16] that supplementation
with a salt-substitute does not alter, nor impact, the per-
ception of saltiness, enjoyability, or overall acceptability
of food. It has also been reported that salt sensitivity is
more common among older individuals and significantly
increases with age [48], which could be considered as a
reason for between-studies differences. Salt sensitivity is
a phenomenon which emphasizes the variation of BP
among individuals in response to dietary salt intake [49],
though the underlying mechanisms of the phenomenon
remain unclear. However, there are some proposed
mechanisms regarding the pathogenesis of salt sensitive
HTN, including impairment in the renin angiotensin
aldosterone system [50], renal trans-membrane sodium
transport [50], the nitric oxide (NO) system, and the vas-
cular endothelium [51]. Notwithstanding, recent studies
indicate that modification of endothelial cell function
and non-osmotic storage of salt could be the result of
changes in endothelial surface layer characteristics.
Therefore, it seems that, in addition to kidney malfunc-
tion, endothelial dysfunction could be considered as an
effective factor related to salt sensitivity and sodium
homeostasis [52].
There is some evidence demonstrating stronger BP re-
ducing effects among elderly people vs young people
[53], and women vs men [54], following a reduction in
sodium intake. However, such discrepancies may be at-
tributed, or indeed, counter-acted when accounting for
baseline BP values and health status. Of note, some
physiological studies have suggested that female hor-
mones (estrogen and progesterone) might be associated
with increased renal sodium reabsorption and water re-
tention [55], and sex hormone genes variants have been
strongly correlated with BP response to a dietary-sodium
intervention [56]. Although there are differences regard-
ing the responses to salt intake with regards to sex, we
could not dichotomize subjects by sex due to insufficient
reporting of BP and sex characteristics. Notwithstanding,
such factors need more detailed investigation.
The current meta-analysis has various limitations, in-
cluding the lack of full-text access to some articles, low
sample size, and that the clinical symptoms of the cases
were varied. Further consideration must be taken should
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clinicians wish to advocate salt substitutes to patients with
multiple co-morbidities; where adverse effects of salt sub-
stitutes in patients with severe renal impairment have
been reported [57, 58] and should, therefore, be consid-
ered when applying salt-substitution strategies in large
and diverse populations. Moreover, five trials (of 11 in-
cluded trials) were conducted in China, which limits the
generalizability of the results. Although there were no spe-
cific heterogeneities between studies, variation in study
duration, which ranged from 8 days to 24months, age of
subjects, ranging from 39.5 and 67.8 years old, and varying
patterns of drugs administration could influence the over-
all results and should be considered as another limitation
of the present study. The inability to conduct subgroup
analysis based on sex, due to insufficiency in the available
data, could be considered as another limitation of the
present study, but was out of the operational control of
the study.
Notwithstanding the limitations, the present study has
numerous strengths; we have analyzed a reasonable num-
ber of studies (11 trials), included a considerable sample
size, reported low heterogeneity, and we also used pre-
specified subgroups to evaluate the effects of modulators.
Conclusions
In conclusion, the results of our meta-analysis highlight
that salt substitutes are an efficacious supplement for
the lowering of SBP and DBP in patients with stage 2
HTN. Thus, it is conceivable that salt substitution may
be a feasible dietary approach for population-level con-
trol of HTN. Moreover, given that HTN has been
ranked the number one risk factor, globally, associated
with the burden of disease [59], identifying appropriate
and sustainable, cultural and economic interventions
with long-term effectiveness is vitally important. Whilst
salt substitution shows promise, a greater number of
studies conducted using large and diverse samples, are
required to affirm their efficacy at the population level.
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